A pilot study into the use of Continuous Venous Hyperfiltration to manage patients in a critical state with dysregulated inflammation. / Estudio piloto sobre el uso de la Hiperfiltración Venosa Continua para el manejo de pacientes en estado crítico con inflamación desregulada.

INTRODUCTION: Haemofiltration paradigms used to manage critically ill patients with a dysregulated inflammatory response (DIR) assess kidney function to monitor its onset, adaptation, and completion. A Continuous Venous Hyperfiltration (CONVEHY) protocol is presented, in which a non-specific adsorption membrane (AN69-ST-Heparin Grafted) is used with citrate as an anticoagulant and substitution fluid. CONVEHY uses tools readily available to achieve kidney related and non-related objectives, and it is guided by the monitoring of pathophysiological responses. OBJECTIVES: To compare the response to an AN69-ST-HG membrane when heparin (He, n=5: Standard protocol) or citrate (Ci, n=6: CONVEHY protocol) was used to evaluate whether a larger study into the benefits of this protocol would be feasible. MATERIALS AND METHODS: In a retrospective pilot study, the benefits of the CONVEHY protocol to manage patients with a DIR in a surgical critical care unit (CCUs) were assessed by evaluating the SOFA (Sequential Organ Failure Assessment) (He 11 ± 2.35; Ci 11 ± 3.63: p=0.54) and APACHE II (He 28.60 ± 9.40; Ci 24 ± 8.46: p=0.93) scores. RESULTS: Nights in hospital (He 35.2 ± 16.3 nights; Ci 9 ± 2.53: p=0.004), hospital admission after discharge from the CCUs (He 40.25 ± 21.82; Ci 13.2 ± 4.09: p=0.063), patients hospitalised >20 days (He 80%; Ci 0%: p=0.048), days requiring mechanical ventilation (He 16 ± 5.66; Ci 4 ± 1.72: p=0.004), and the predicted (55.39 ± 26.13%) versus real mortality in both groups (9.1%: p=0.004). CONCLUSIONS: The CONVEHY protocol improves the clinical responses of patients with DIR, highlighting the potential value of performing larger and confirmatory studies.

Antimicrobial alumina nanobiostructures of disulfide- and triazole-linked peptides: Synthesis, characterization, membrane interactions and biological activity.

Due to the its physical-chemical properties, alumina nanoparticles have potential applications in several areas, such as nanobiomaterials for medicinal or orthodontic implants, although the introduction of these devices poses a serious risk of microbial infection. One convenient strategy to circumvent this problem is to associate the nanomaterials to antimicrobial peptides with broad-spectrum of activities. In this study we present two novel synthesis approaches to obtain fibrous type alumina nanoparticles covalently bound to antimicrobial peptides. In the first strategy, thiol functionalized alumina nanoparticles were linked via disulfide bond formation to a cysteine residue of an analog of the peptide BP100 containing a four amino acid spacer (Cys-Ala-Ala-Ala). In the second strategy, alumina nanoparticles were functionalized with azide groups and then bound to alkyne-decorated analogs of the peptides BP100 and DD K through a triazole linkage obtained via a copper(I)-catalyzed cycloaddition reaction. The complete physical-chemical characterization of the intermediates and final materials is presented along with in vitro biological assays and membrane interaction studies, which confirmed the activity of the obtained nanobiostructures against both bacteria and fungi. To our knowledge, this is the first report of aluminum nanoparticles covalently bound to triazole-peptides and to a disulfide bound antimicrobial peptide with high potential for biotechnological applications.

Nanobiostructure of fibrous-like alumina functionalized with an analog of the BP100 peptide: Synthesis, characterization and biological applications.

The functionalization of alumina nanoparticles of specific morphology with antimicrobial peptides (AMP) can be a promising strategy for modeling medical devices and packaging materials for cosmetics, medicines or food, since the contamination by pathogens could be reduced. In this paper, we show the synthesis of a fibrous-like alumina nanobiostructure, as well as its functionalization with the peptide EAAA-BP100, an analog of the antimicrobial peptide BP100. The antibacterial activity of the obtained material against some bacterial strains is also investigated. The covalent binding of the peptide to the nanoparticles was promoted by a reaction between the carboxyl group of the glutamate side chain (E1) of the peptide and the amino groups of the alumina nanoparticles, previously modified by reaction with 3-aminopropyltrietoxysilane (APTES). The functionalized nanoparticles were characterized by zeta potential measurements, Fourier transform infrared spectroscopy, and other physicochemical techniques. Although the obtained alumina nanobiostructure shows a relatively low degree of substitution with EAAA-BP100, antibacterial activities against Escherichia coli and Salmonella typhimurium strains are appreciably higher than the activities of the free peptide. The obtained results can affect the design of new hybrid nanobiomaterials based on nanoparticles functionalized with AMP.

Correlation between oxyhaemoglobin saturation by pulse oximetry and partial pressure of oxygen in patients with acute respiratory failure. / Correlación entre la saturación de oxihemoglobina por pulsioximetría y la presión arterial de oxígeno en pacientes con insuficiencia respiratoria aguda.

OBJECTIVES: To ascertain the correlation between the partial pressure of oxygen (PaO2) and oxyhaemoglobin saturation by pulse oximetry (SpO2) in patients who were admitted to the emergency department with suspected acute respiratory failure. MATERIAL AND METHODS: A prospective, observational multicentre study was conducted in the emergency departments of 3 Spanish hospitals. RESULTS: The study included 166 patients who presented mean±standard deviation PaO2, SpO2 and fraction of inspired oxygen (FiO2) values of 61.64±17.3mmHg, 87.61±8.8% and 0.28±0.15%, respectively. The median PaO2/FiO2 and SpO2/FiO2 ratios were 256.6 and 359.2, respectively. The correlation between PaO2/FiO2 and the SpO2/FiO2 was 0.745 (P<.001). CONCLUSIONS: The SpO2/FiO2 ratio can be used to calculate PaO2/FiO2 and determine the oxygenation state of patients with acute respiratory failure.

Assessing the Construct Validity and Internal Reliability of the Screening Tool Test Your Memory in Patients with Chronic Pain.

Patients with chronic pain often complain about cognitive difficulties, and since these symptoms represent an additional source of suffering and distress, evaluating the cognitive status of these patients with valid and reliable tests should be an important part of their overall assessment. Although cognitive impairment is a critical characteristic of pain, there is no specific measure designed to detect these effects in this population. The objective was to analyze the psychometric properties of the "Test Your Memory" (TYM) test in patients with chronic pain of three different origins. A cross-sectional study was carried out on 72 subjects free of pain and 254 patients suffering from different types of chronic pain: neuropathic pain (104), musculoskeletal pain (99) and fibromyalgia (51). The construct validity of the TYM was assessed using the Mini-Mental State Examination (MMSE), Hospital Anxiety and Depression Scale (HADs), Index-9 from MOS-sleep, SF-12, and through the intensity (Visual Analogical Scale) and duration of pain. An exploratory factor analysis was also performed and internal reliability was assessed using Cronbach's alpha. After adjusting for potential confounders the TYM could distinguish between pain and pain-free patients, and it was correlated with the: MMSE (0.89, p<0.001); HAD-anxiety (-0.50, p<0.001) and HAD-depression scales (-0.52, p<0.001); MOS-sleep Index-9 (-0.49, p<0.001); and the physical (0.49, p < .001) and mental components (0.55, p < .001) of SF-12. The exploratory structure of the TYM showed an 8-factor solution that explained 53% of the variance, and Cronbach's alpha was 0.66. The TYM is a valid and reliable screening instrument to assess cognitive function in chronic pain patients that will be of particular value in clinical situations.

Toxicity study about a medicinal plant Casearia sylvestris: A contribution to the Brazilian Unified Health System (SUS).

ETHNOPHARMACOLOGICAL RELEVANCE: Casearia sylvestris S.w (Salicaceae) is catalogued by the Brazilian Unified Health System as a plant of interest for the Brazilian population with the purpose of treating inflammatory disorders, such as pain and gastrointestinal disorders based on the folk use and some literature about efficacy; however, no toxicological studies concerned the safety of extract fluid of this plant have been reported. AIM OF THE STUDY: The present study was carried out to evaluate the acute and subchronic toxicity of the hydroethanolic extract fluid (FE) obtained from leaves of C. sylvestris in Wistar rats. MATERIALS AND METHODS: In the acute toxicity test three female Wistar rats were treated with a single dose of FE (2000 mg/kg) administered by oral gavage and observed for 14 days in order to identify signs of toxicity or death. In subchronic toxicity study animals received, by daily gavage three doses 60, 120 and 240 mg/kg of the FE of the plant for 28 and 90 days. The animals were observed daily for clinical signs and mortality. Body weight and food consumption were measured weekly and at the end of treatment were analysed hematological, biochemical and histopathological parameters. Also was analysed the cellularity of bone marrow and spleen. Moreover, phytochemical analysis by HPLC-PDA-ESI(+)/MS and CG/MS/EI was carried out to qualify the constituents of the extract. RESULTS: The results of acute study indicated that the LD50 is higher than 2000 mg/kg and at 28 and 90 day oral toxicity showed that there were no toxic effects detected in any of the parameters evaluated: body weight and relative organ weight, general behavioral changes, haematological and biochemical parameters and histopathological examination. The analysis by HPLC-PDA-ESI(+)/MS and CG/MS/EI identified the flavonoids rutin, quercetin and luteolin and also chlorogenic on the extract. CONCLUSION: Based on this study the hydroethanolic fluid extract of C. sylvestris could be safe even when used over a long period for therapeutic uses proposed by the Brazilian Unified Health System.

[Perioperative management of direct oral anticoagulant in emergency surgery and bleeding. Haemostasis monitoring and treatment]. / Manejo perioperatorio de los anticoagulantes orales directos en cirugía urgente y sangrado. Monitorización y tratamiento hemostático.

There is an almost unanimous consensus on the management of the direct new oral anticoagulants, dabigatran, rivaroxaban, and apixaban in elective surgery. However, this general consensus does not exist in relation with the direct new oral anticoagulants use in emergency surgery, especially in the bleeding patient. For this reason, a literature review was performed using the MEDLINE-PubMed. An analysis was made of the journal articles, reviews, systematic reviews, and practices guidelines published between 2000 and 2014 using the terms "monitoring" and "reversal". From this review, it was shown that the routine tests of blood coagulation, such as the prothrombin time and activated partial thromboplastin time, have a limited efficacy in the perioperative control of blood coagulation in these patients. There is currently no antidote to reverse the effects of these drugs, although the possibility of using concentrated prothrombin complex and recombinant activated factor vii has been suggested for the urgent reversal of the anticoagulant effect.

Manejo de la vía aérea de pacientes con obstrucción severa de la luz glótica. Experiencia con el estilete óptico de Bonfils / Airway management of patients with severe obstruction of the glottic opening. Experience with the Bonfils optical stylet

No disponible

Growth inhibition and antioxidative response of wood decay fungi exposed to plant extracts of Casearia species.

UNLABELLED: Ligninolytic fungi take part in critical processes in ecosystems such as nutrient recycling; however, some fungal species can be pathogenic to forest and urban trees and deteriorate wood products. The tropical flora is an important source of antimicrobial compounds environmentally safer than traditional wood preservatives. Therefore, this study aimed to evaluate the inhibitory activity of ethanol plant extracts of Casearia sylvestris and Casearia decandra on the white-rot wood decay basidiomycetes Trametes villosa and Pycnoporus sanguineus. In addition, the effect of the extracts on the fungal antioxidative metabolism was studied. Among the different substances present in the extracts, the phytochemical analyses identified a clerodane diterpenoid (C. sylvestris) and cinnamic acid, hydroquinone and ß-sitosterol (C. decandra). The extracts inhibited the fungi up to 70% and caused hyphal morphology changes. The extracts triggered oxidative stress process as indicated by the increased levels of the antioxidant enzymes catalase and glutathione reductase. Therefore, the Casearia extracts are a potential source of natural biocides to control wood decay fungi, and one of the mechanisms of action is the oxidative stress. SIGNIFICANCE AND IMPACT OF THE STUDY: The Casearia plant extracts exhibited important antifungal activity on wood decay fungi and triggered oxidative stress process, an inhibitory mechanism rarely studied in filamentous fungi exposed to plant extracts. Therefore, a starting point was provided for the development of natural compounds-based products as an alternative to chemical fungicides. In addition, subsidies were given to further studies in order to elucidate in more detail how compounds present in extracts of native tropical plants affect the physiology of fungi.

Láser en ortodoncia / Laser in orthodontics

La primera aplicación del laser en un diente fue realizada en 1965. Desde entonces ha presentado una constante evolución y desarrollo. La tecnología laser permite realizar procedimientos en tejidos duros y blandos, pudiendo ser utilizado con las siguientes finalidades: como prevención de la desmineralización, en la adhesión y remoción de brackets, en la reducción del dolor producto del movimiento dental, en la reparación ósea después de la expansión, en diversas cirugías y otras aplicaciones más. El objetivo de este artículo es realizar una revisión bibliográfica sobre algunos de los usos, ventajas y características del laser en Ortodoncia.

The first application of laser in a tooth was made in 1965. Since then this tecnology had a constant evolution and development. Laser technology allows procedures in hard and soft tissues, it can be used for the following purposes: prevention of demineralization, bonding and debonding of brackets, to reduce pain resulting from tooth movement, bone repair after expansion, surgeries and other applications. The aim of this article is to review the literature on some of the uses, advantages and features of the laser in orthodontics.

The perioperative management of new direct oral anticoagulants: a question without answers.

New direct oral anticoagulant agents (DOAC) are currently licensed for thromboprophylaxis after hip and knee arthroplasty and for long-term prevention of thromboembolic events in non-valvular atrial fibrillation as well as treatment and secondary prophylaxis of venous thromboembolism. Some other medical indications are emerging. Thus, anaesthesiologists are increasingly likely to encounter patients on these drugs who need elective or emergency surgery. Due to the lack of experience and data, the management of DOAC in the perioperative period is controversial. In this article, we review available information and recommendations regarding the periprocedural management of the currently most clinically developed DOAC, apixaban, dabigatran, and rivaroxaban. We discuss two trends of managing patients on DOAC for elective surgery. The first is stopping the DOAC 1-5 days before surgery (depending on the drug, patient and bleeding risk) without bridging. The second is stopping the DOAC 5 days preoperatively and bridging with low-molecular-weight heparin. The management of patients on DOAC needing emergency surgery is also reviewed. As no data exist for the use of haemostatic products for the reversal of the anticoagulant effect in these cases, rescue treatment recommendations are proposed.

Potencial terapéutico de los cannabinoides / Therapeutic potential cannabinoids

Los cannabinoides demuestran eficacia en modelos experimentales de dolor agudo y crónico. Parecen seguros en los ensayos desarrollados para algunas indicaciones de dolor y otras. Las nuevas tecnologías han abierto nuevas posibilidades de tratamiento al proporcionar nuevas vías de administración. Se precisan ensayos en pacientes para determinar el verdadero rol de estas sustancias en el tratamiento del dolor (AU)

Cannabinoids show efficacy in experimental models of acute and chronic pain. They seem safe in trials developed for some indications of pain and others. New technologies have opened new possibilities for treatment by providing new routes of administration. Trials in patients are needed to determine the true role of these substances in the treatment of pain (AU)

Tratamiento de epicondilitis refractaria con neurotoxina botulínica tipo A libre de complejo proteínico / No disponible

Introducción: La epicondilitis o “codo de tenista” es un cuadro que se caracteriza por dolor en la inserción proximal del músculo extensor radial corto del carpo. El tratamiento de este cuadro clásicamente se ha basado en fisioterapia e infiltración con corticoides, así como el uso de ortesis. La cirugía se recomienda cuando las estrategias conservadoras no controlan los síntomas después de 6-12 meses de tratamiento. La toxina botulínica es una opción terapéutica cuando fracasan medidas conservadoras. Material y métodos: Presentamos 3 pacientes diagnosticados previamente de epicondilitis de más de 6 meses de evolución y que habían sido sometidos de forma ambulatoria a los tratamiento habituales sin éxito, a los cuales se les administró toxina botulínica A libre de complejo proteico (50 UI) en un solo punto de aplicación. Se evaluó la intensidad del dolor en ambos pacientes usando una escala analógica visual (EVA), en la que el 0 representa ningún dolor y 10 significa el dolor más intenso que han experimentado tanto a la palpación como con la maniobra de extensión resistida de la muñeca. Resultados: Se obtuvo una reducción importante del dolor en los 3 pacientes tratados al primer mes de su administración, con resolución total del mismo a los 3 meses. Este beneficio se mantuvo al menos durante los 6 meses de estudio. Conclusiones: La epicondilitis refractaria a tratamientos conservadores puede ser tratada eficazmente con toxina botulínica A libre de complejo proteínico (AU)

Introduction: Epicondylitis or “tennis elbow” is a condition characterized by pain in the proximal insertion of the extensor Carpi radialis brevis muscle. Treatment of this condition has classically been based on physiotherapy and infiltration with corticosteroids, as well as the use of orthoses. Surgery is recommended when the conservative strategies do not control symptoms after 6-12 months of treatment. Botulin toxin is a therapeutic option when conservative measures are failing Material and methods: We present 3 patients diagnosed of epicondylitis for more than 6 months, and which had been subjected to the usual treatment without success, which will manage with free protein complex botulinum toxin (50 IU) at a single point of application on an outpatient basis. The intensity of the pain in the 3 patients were evaluated using an analog scale visual (EVA) in which 0 represents no pain and 10 means more intense pain experienced with resisted wrist extension maneuver both palpation. Results: We obtained a significant reduction of pain in 3 patients treated to the first month of his administration with total resolution at 3 months. This benefit was maintained at least during 6 months. Conclusions: refractory to conservative treatment can be effectively treated with free protein complex botulinum toxin (AU)

Manejo de los anticoagulantes orales de acción directa en el período perioperatorio y técnicas invasivas / Management of direct action oral anticoagulants in the peri-operative period and invasive techniques

El manejo de los nuevos anticoagulantes orales de acción directa (ACOD) en pacientes en tratamiento prolongado supone la necesidad de adecuar el riesgo hemorrágico de su administración con el riesgo trombótico de su supresión. En el presente artículo se proponen recomendaciones para su manejo: A) tromboprofilaxis y anestesia regional: la realización de anestesia regional si se administra un ACOD como tromboprofilaxis precisa de unos intervalos de seguridad basados en sus parámetros farmacocinéticos; B) manejo de los ACOD en cirugía programada: en pacientes con función renal normal y riesgos hemorrágico/trombótico bajos, suspender el ACOD 2 días antes de la cirugía; si el riesgo hemorrágico/trombótico es alto y/o la función renal está alterada, se propone una terapia puente con una heparina de bajo peso molecular desde 5 días antes de la cirugía, y C) manejo de los ACOD en cirugía urgente y hemorragia relacionada: no se recomienda la administración sistemática de hemostáticos de forma profiláctica. En caso de hemorragia aguda que pueda poner en riesgo la vida del paciente (por volumen o por localización), se debe valorar la administración de concentrados de complejo protrombínico, plasma fresco o factor VIIa, junto con las medidas generales de control de la hemorragia aguda. Estas recomendaciones se deben considerar en el contexto de empleo de unos fármacos que no poseen antídoto específico, cuya monitorización con los tests habituales de la coagulación no está sistematizada y con los que existe una experiencia limitada. Consideramos necesaria su revisión en un futuro, según estudios futuros y la experiencia clínica que se vaya obteniendo(AU)

The new direct-acting oral anticoagulants (ACOD) in patients on prolonged treatment require the need to balance the risk of haemorrhage by administering them against the risk of thrombosis on withdrawing them. Recommendations for their management are proposed in the present article: A) Thromboprophylaxis and general anaesthesia: the performing of regional anaesthesia if administered with an ACOD as thromboprophylaxis requires some safety intervals based on their pharmacokinetic parameters; B) Management of ACOD in elective surgery: in patients with normal renal function and a low haemorrhage/thrombosis risk, stop the ACOD two days before the surgery; it the haemorrhage/thrombosis risk is high and/or renal function is impaired, therapy with a low molecular weight heparin is proposed from 5 days prior to the surgery, and C) Management of ACOD in urgent surgery and associated haemorrhage: the systematic prophylactic administration of haemostatics is recommended. In the event of acute bleeding that may place the life of the patient at risk (due to volume or location), the administration of concentrated prothrombin complex, fresh plasma, or factor VIIa, must be assessed, together with general control measures of acute haemorrhage. These recommendations should be considered in the context of the use drugs that do have a specific antidote, where their monitoring by the usual coagulation tests is not routine, and with those in which there is limited experience. We believe they need to be reviewed in the future, depending on further studies and clinical experience obtained(AU)